[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 671
Citations 0
Comment & Response
December 12, 2019

Late Recurrences After Estrogen Receptor–Positive Breast Cancer

Author Affiliations
  • 1Women’s College Research Institute, Women’s College Hospital, Toronto, Ontario, Canada
  • 2Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
  • 3Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
JAMA Oncol. 2020;6(2):301-302. doi:10.1001/jamaoncol.2019.5579

To the Editor The article by Yu et al1 is fascinating and important. They describe the hazard rates for distant recurrence in the 25-year period following a diagnosis of estrogen receptor–positive breast cancer. Patients were subdivided into whether they received tamoxifen or no endocrine therapy (randomly assigned) and if they had a luminal A or luminal B tumor subtypes. The benefit of tamoxifen in 25-year distant recurrence–free survival was substantial in both groups (luminal A subtype: 70% [95% CI, 62%-79%] for untreated patients vs 87% [95% CI, 82%-93%] for treated patients; P < .001; luminal B subtype: 54% [95% CI, 42%-70%] for untreated patients vs 67% [95% CI, 56%-82%] for treated patients; P = .04). These data should encourage the use of tamoxifen when appropriate. They had a substantial follow-up time (25 years), which is necessary to fully appreciate the influence of any intervention in patients with low-risk breast cancer. Overall, 21.6% of the patients experienced a distant recurrence.1

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×